This strategy – combining tumor-targeted drug delivery with schedule-based PARP inhibition – enabled dose escalation of both olaparib and CRLX101 to levels previously unattainable in clinical settings, resulting in preliminary clinical activity. Here, PARP1 is linked to neoplasm.